Clinical effects of infusions into chimpanzees of primed autologous cultured T-cells.
As a model to study the possible early side effects of cultured T-cells (CTC) as a potential for adoptive cellular immunotherapy of human tumors, chimpanzees received iv infusions of 10(9) autologous, mixed lymphocyte culture-primed CTC. Complete blood counts, urinalyses, chest X-rays, blood chemistries, and serum immunoelectrophoresis were normal, and serologic studies were negative throughout the 3 weeks of observation. Serial transaminase levels were followed in 2 chimps, and mild increases in serum glutamic-oxaloacetic transaminase were seen in both and serum glutamic-pyruvic transaminase in 1 at 24 hours following each CTC infusion, but the levels returned to normal within 7 days. A liver biopsy specimen was normal. Fluorescence-activated cell sorter analysis of cells incubated with day 28 serum revealed weak labeling of only phytohemagglutinin (PHA)-stimulated lymphoblasts and of CTC, suggesting that a weak anti-PHA antibody was generated. These studies indicate that infusions of autologous, in vitro-primed CTC are accompanied by little clinical toxicity in the chimp model but that they may be weakly immunogenic.
D000818:Animals; D001772:Blood Cell Count; D002478:Cells, Cultured; D004798:Enzymes / Q000097:blood; D007106:Immune Sera; D007111:Immunity, Cellular; D008099:Liver / Q000378:metabolism; D002679:Pan troglodytes; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D013936:Thymidine / Q000378:metabolism; D014182:Transplantation, Autologous
D004798:Enzymes; D007106:Immune Sera; D013936:Thymidine